BioSpace News Archive

Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, UK.

KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of financing.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022.

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, opened its new facility in Newark, California, where it will relocate its corporate headquarters this year.

The contract research organization (CROs) services market is expected to reach valuation US$ 111.26 billion by 2028, growing at a CAGR of 10.1% from 2021 to 2030.

Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease.

Rising number of clinical trials across the globe, high healthcare research & development investments, and increasing research outsourcing activities are driving contract research outsourcing market revenue growth.

The pharmaceutical and healthcare sector has witnessed drastic changes in the recent years primarily due to growing prevalence of diseases, technological advancements in medicine, and increasing investments in research and development activities.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announces positive analysis of the long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19, with positive immunological results obtained at 6 months on T cell memory response in the vaccinated subjects. In parallel, the resolution of local indurations related to T cell mechanism of action (1) and the good safety profile were confirmed.

Featured this week at HIMSS22, LG Electronics’ new Business Innovation Center is the first comprehensive LG technology and education hub to focus on commercial displays and devices designed for medical environments.